Lexaria Bioscience (LEXX) Operating Leases (2020 - 2026)
Lexaria Bioscience (LEXX) posted Operating Leases of $53679.0 for Q2 2026, down 43.13% sequentially from $94386.0 in Q1 2026, and down 38.1% YoY from $86714.0 in Q2 2025.
Lexaria Bioscience (LEXX) Operating Leases (2020 - 2026) Analysis & Trends
Lexaria Bioscience has reported Operating Leases for 6 years, with the latest figure at $53679.0 in Q2 2026.
- Quarterly Operating Leases fell 38.1% year-over-year to $53679.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $53679.0 (down 38.1% YoY) and the FY2025 annual result came in at $109319.0, down 20.42% from the prior year.
- Operating Leases retreated to $53679.0 in Q2 2026 per LEXX's latest filing, from $94386.0 in the prior quarter.
- Over five years, Operating Leases peaked at $137366.0 in Q3 2024 and troughed at $18339.0 in Q2 2022.
- A 4-year average of $85644.6 and a median of $98153.0 in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2025: Operating Leases plunged 81.41% in 2022, then changed 0.0% in 2025.
- Over 4 years, Operating Leases stood at $18339.0 in 2022, then jumped by 455.76% to $101920.0 in 2024, then changed by 0.0% to $101920.0 in 2025, then sank by 47.33% to $53679.0 in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $53679.0, $94386.0, and $101920.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 53,679.00 |
| Feb 28, 2026 | 94,386.00 |
| Nov 30, 2025 | 101,920.00 |
| Aug 31, 2025 | 109,319.00 |
| May 31, 2025 | 86,714.00 |
| Feb 28, 2025 | 123,723.00 |
| Nov 30, 2024 | 101,920.00 |
| Aug 31, 2024 | 137,366.00 |
| May 31, 2022 | 18,339.00 |
| Feb 28, 2022 | 29,080.00 |
| Aug 31, 2021 | 49,989.00 |
| May 31, 2021 | 98,649.00 |
| Feb 28, 2021 | 70,156.00 |
| Nov 30, 2020 | 116,664.00 |
| Aug 31, 2020 | 36,038.00 |